Aldeyra to screen ADX-629, reproxalap for COVID-19 treatment

Aldeyra Therapeutics plans to screen its reactive aldehyde species inhibitors for anti-inflammatory and antiviral activity in the treatment of COVID-19, according to a press release.

The company’s ADX-629 and reproxalap are structurally related to chloroquine and hydroxychloroquine, the release said. Both drugs are currently in clinical testing for the treatment of COVID-19.

A proposal has been submitted to the Biomedical Advanced Research and Development Authority to develop ADX-629 for this purpose.

“We are committing scientific expertise and development resources associated with our RASP platform to help reduce the impact of the COVID-19 global health care crisis,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release. “Given the strong association between RASP and acute respiratory distress syndrome, as well as the structural similarity of reproxalap and ADX-629 to chloroquines, we are researching the potential of our novel RASP inhibitors to mitigate the clinical severity of COVID-19 infection.”

Aldeyra Therapeutics plans to screen its reactive aldehyde species inhibitors for anti-inflammatory and antiviral activity in the treatment of COVID-19, according to a press release.

The company’s ADX-629 and reproxalap are structurally related to chloroquine and hydroxychloroquine, the release said. Both drugs are currently in clinical testing for the treatment of COVID-19.

A proposal has been submitted to the Biomedical Advanced Research and Development Authority to develop ADX-629 for this purpose.

“We are committing scientific expertise and development resources associated with our RASP platform to help reduce the impact of the COVID-19 global health care crisis,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release. “Given the strong association between RASP and acute respiratory distress syndrome, as well as the structural similarity of reproxalap and ADX-629 to chloroquines, we are researching the potential of our novel RASP inhibitors to mitigate the clinical severity of COVID-19 infection.”

    See more from COVID-19 Resource Center